The 2019 novel coronavirus (2019-nCoV), officially named as COVID-19 pandemic by the WHO,...
Biophytis and SGS partner to test Sarconeos in Covid-19 patients
French biotech firm Biophytis will assess its Sarconeos (BIO101) drug as a treatment for respiratory failure caused by Covid-19 after partnering with contract research organisation (CRO) SGS.
Corvus starts Phase I trial of immunotherapy to treat Covid-19
Corvus Pharmaceuticals has launched a Phase I clinical trial of its new immunotherapy product, CPI-006, for the treatment of patients with Covid-19.
CSL Behring evaluates monoclonal antibody in Covid-19 patients
CSL Behring has started enrolment in a Phase II clinical trial of CSL312 for the treatment of patients with severe respiratory distress caused by Covid-19-related pneumonia.
Immune Regulation and DynPort to trial Covid-19 drug candidate
Biotechnology company Immune Regulation has signed a teaming agreement with DynPort Vaccine to assess ILR201104 as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19 in the US.
Regeneron launches Phase III Covid-19 prevention trial
Regeneron Pharmaceuticals has started Phase III clinical trials of its double antibody cocktail, REGN-COV2, for the treatment and prevention of Covid-19.
India’s Zydus gets Mexican approval to trial Desidustat for Covid-19
India-based pharmaceutical company Zydus has received approval from the Mexican regulatory authority, COFEPRIS, to assess Desidustat as a potential Covid-19 treatment.
WHO stops hydroxychloroquine and lopinavir/ritonavir trial arms
The World Health Organization (WHO) has decided to discontinue hydroxychloroquine and lopinavir/ritonavir arms in its Solidarity Trial, which is being conducted to assess potential treatments for hospitalised Covid-19 patients.
India approves second Covid-19 vaccine for clinical trials
Zydus Cadila has secured regulatory approval from the Drug Controller General of India (DCGI) to conduct Phase I/II human trials of its Covid-19 vaccine candidate, named ZyCoV-D.
Sanofi and Regeneron’s Kevzara fails in Phase III Covid-19 trial
Sanofi and Regeneron Pharmaceuticals have reported that a Phase III clinical trial of rheumatoid arthritis drug Kevzara (sarilumab) failed to meet its primary and key secondary endpoints in Covid-19 patients who required mechanical ventilation in the US.
First Covid-19 vaccine candidate trial begins in Australia
The first clinical trials of a Covid-19 vaccine developed in Australia have commenced at Royal Adelaide Hospital's PARC Clinical Research facility.